Ensuring Patient Access to Critical Breakthrough Products Act
U.S. Congress · HR5343 ·
Progression
Timing in context
Primary sponsor's contributions received (same period)
Adjacency in time is shown for context; it is not evidence of cause. Funded ≠ false — see the methodology.
What the bill says
Introduced 2025-09-15. Latest action: Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 37 - 3.
Sponsors
- Blake D. Moore (primary)
- Jake Auchincloss
- Cliff Bentz
- Gus M. Bilirakis
- Ami Bera
- Brendan F. Boyle
- Nanette Diaz Barragán
- Aaron Bean
- Steve Cohen
- Earl L. "Buddy" Carter
- J. Luis Correa
- Angie Craig
- Jason Crow
- Mike Carey
- Juan Ciscomani
- Suzan K. DelBene
- Neal P. Dunn
- Sharice Davids
- Brian K. Fitzpatrick
- Michelle Fischbach
- Josh Gottheimer
- Maggie Goodlander
- Kevin Hern
- Chrissy Houlahan
- John Joyce
- Mike Kelly
- David Kustoff
- Young Kim
- Jennifer A. Kiggans
- Mike Kennedy
- Zoe Lofgren
- Ted Lieu
- Michael Lawler
- Sam T. Liccardo
- Nicole Malliotakis
- Daniel Meuser
- Carol D. Miller
- Gregory F. Murphy
- Frank J. Mrvan
- Richard McCormick
- Kevin Mullin
- Celeste Maloy
- Jay Obernolte
- Burgess Owens
- Scott H. Peters
- Jimmy Panetta
- Chris Pappas
- Brittany Pettersen
- Deborah K. Ross
- John H. Rutherford
- Maria Elvira Salazar
- Marilyn Strickland
- Terri A. Sewell
- Bradley Scott Schneider
- Darren Soto
- Mary Gay Scanlon
- Haley M. Stevens
- Claudia Tenney
- Lori Trahan
- David G. Valadao
- Randy K. Weber, Sr.
- George Whitesides
- Rudy Yakym III
Text versions
- Introduced in House — 2025-09-15 — XML
What analysts say
CBO cost estimates
-
H.R. 5343, Ensuring Patient Access to Critical Breakthrough Products Act
— 2025-11-19
As ordered reported by the House Committee on Ways and Means on September 17, 2025
Full estimate published at cbo.gov; it will appear here once an archived or committee-report copy is available.
What politicians say
No linked claims or utterances yet — no one on record has cited this measure to justify a public argument.
Action History
| Date | Action |
|---|---|
| 2025-09-17 | Committee Consideration and Mark-up Session Held |
| 2025-09-17 | Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 37 - 3. |
| 2025-09-15 | Introduced in House |
| 2025-09-15 | Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
Lobbying on this bill
Showing 2 of 2 bill mentions.
Honesty note: each filer below disclosed lobbying on this bill — that much the filing tells us. But the dollar figure is their total lobbying spend for the whole quarter across all their issues, not the amount spent on this bill, and the filing never says whether they supported or opposed it.
| Registrant (lobbying firm) | Client | Period | Reported quarterly amount | Extraction |
|---|---|---|---|---|
| RS GROUP CONSULTING LLC | INSIGHTEC, INC. | Q1 2026 | not reported | |
| RS GROUP CONSULTING LLC | INSIGHTEC, INC. | Q1 2026 | not reported |
Source: Senate LDA filings.